Progenics Pharmaceuticals Sets Third Quarter Financial Results Conference Call for November 11

Progenics Pharmaceuticals Sets Third Quarter Financial Results Conference Call
for November 11

TARRYTOWN, N.Y., Nov. 4, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Inc. (Nasdaq:PGNX) announced that it will host a conference call and webcast
to review third quarter financial results on Monday, November 11, at 8:30 a.m.
ET.

To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001
(international) and reference conference ID 92604931. A live webcast will be
available in the Media Center of the Progenics website, www.progenics.com, and
a replay will be available there for two weeks.

About Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for
oncology, with a pipeline that includes several product candidates in
late-stage clinical development. Progenics' first-in-class PSMA-targeted
technology platform includes an antibody-drug conjugate therapeutic and a
small molecule targeted imaging agent, both in Phase 2 clinical trials. Among
other assets in its pipeline of targeted radiotherapy and molecular imaging
compounds is Azedra^™, an ultra-orphan radiotherapy candidate in phase 2 under
an SPA.Progenics' first commercial product, Relistor^® (methylnaltrexone
bromide) for opioid-induced constipation, is partnered with and marketed by
Salix Pharmaceuticals, Inc.Ono Pharmaceutical Co. is developing Relistor in
Japan. Please visit us at www.progenics.com.

(PGNX-F)

CONTACT: Kathleen Fredriksen
         Corporate Development
         (914) 789-2871
         kfredriksen@progenics.com

company logo